274 related articles for article (PubMed ID: 35101971)
1. In vivo imaging of nanoparticle-labeled CAR T cells.
Kiru L; Zlitni A; Tousley AM; Dalton GN; Wu W; Lafortune F; Liu A; Cunanan KM; Nejadnik H; Sulchek T; Moseley ME; Majzner RG; Daldrup-Link HE
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35101971
[TBL] [Abstract][Full Text] [Related]
2. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
3. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
4. Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models.
Wu WE; Chang E; Jin L; Liu S; Huang CH; Kamal R; Liang T; Aissaoui NM; Theruvath AJ; Pisani L; Moseley M; Stoyanova T; Paulmurugan R; Huang J; Mitchell DA; Daldrup-Link HE
Invest Radiol; 2023 Jun; 58(6):388-395. PubMed ID: 36729074
[TBL] [Abstract][Full Text] [Related]
5. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
Front Immunol; 2021; 12():691741. PubMed ID: 34211478
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging.
Xie T; Chen X; Fang J; Xue W; Zhang J; Tong H; Liu H; Guo Y; Yang Y; Zhang W
Cytotherapy; 2021 Mar; 23(3):211-222. PubMed ID: 33334686
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
8. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.
Shao F; Long Y; Ji H; Jiang D; Lei P; Lan X
Theranostics; 2021; 11(14):6800-6817. PubMed ID: 34093854
[TBL] [Abstract][Full Text] [Related]
9.
Hunger J; Schregel K; Boztepe B; Agardy DA; Turco V; Karimian-Jazi K; Weidenfeld I; Streibel Y; Fischer M; Sturm V; Santarella-Mellwig R; Kilian M; Jähne K; Sahm K; Wick W; Bunse L; Heiland S; Bunse T; Bendszus M; Platten M; Breckwoldt MO
Theranostics; 2023; 13(15):5170-5182. PubMed ID: 37908732
[No Abstract] [Full Text] [Related]
10. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
11. Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI.
Dubois VP; Sehl OC; Foster PJ; Ronald JA
Mol Imaging Biol; 2022 Apr; 24(2):298-308. PubMed ID: 34786668
[TBL] [Abstract][Full Text] [Related]
12. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
[TBL] [Abstract][Full Text] [Related]
13. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
15. Treating osteosarcoma with CAR T cells.
Köksal H; Müller E; Inderberg EM; Bruland Ø; Wälchli S
Scand J Immunol; 2019 Mar; 89(3):e12741. PubMed ID: 30549299
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
17. Potential of human γδ T cells for immunotherapy of osteosarcoma.
Li Z
Mol Biol Rep; 2013 Jan; 40(1):427-37. PubMed ID: 23065272
[TBL] [Abstract][Full Text] [Related]
18. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
19. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
20. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
